Ob/Gyn Updated
Your Web destination for the latest in Evidence based Obstetrics, Gynecology and Women’s health.
Showing posts with label
CDK4/6 inhibitor ribociclib
.
Show all posts
Showing posts with label
CDK4/6 inhibitor ribociclib
.
Show all posts
Friday, June 23, 2017
Novartis Breast Cancer drug Kisqali wins market approval in European Union as first-line treatment for HR+/HER2-
›
European Medicines Agency (EMA) panel approves Kisqali (CDK4/6 inhibitor ribociclib) in combination with hormone therapy as a first-l...
›
Home
View web version
